iCAD, Inc. (NASDAQ:ICAD – Get Free Report) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 451,300 shares, a growth of 9.2% from the March 15th total of 413,100 shares. Currently, 1.8% of the shares of the stock are sold short. Based on an average trading volume of 210,300 shares, the short-interest ratio is currently 2.1 days.
iCAD Trading Down 1.3 %
Shares of NASDAQ:ICAD traded down $0.02 during trading on Wednesday, reaching $1.58. The company had a trading volume of 41,102 shares, compared to its average volume of 196,744. The company has a fifty day moving average of $1.62 and a two-hundred day moving average of $1.59. The stock has a market capitalization of $41.93 million, a P/E ratio of -7.36 and a beta of 1.34. iCAD has a 12 month low of $1.05 and a 12 month high of $3.97.
iCAD (NASDAQ:ICAD – Get Free Report) last issued its quarterly earnings results on Tuesday, March 12th. The technology company reported ($0.02) EPS for the quarter. The company had revenue of $4.74 million during the quarter. iCAD had a negative return on equity of 21.63% and a negative net margin of 27.08%.
Hedge Funds Weigh In On iCAD
iCAD Company Profile
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography.
Further Reading
- Five stocks we like better than iCAD
- Canadian Penny Stocks: Can They Make You Rich?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Airline Stocks – Top Airline Stocks to Buy Now
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
- How Investors Can Find the Best Cheap Dividend Stocks
- Abbott Laboratories Outlook is Healthy: Buy the Dip
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.